Multi-epitope peptide melanoma vaccine

A multi-antigenic peptide-based cancer vaccine composed of synthetic peptides derived from three melanocyte differentiation antigens—MART‑1 (Melanoma Antigen Recognized by T cells 1 or Melan-A), gp100 (Glycoprotein 100 or PMEL), and Tyrosinase. These antigens are highly expressed in both cutaneous and uveal melanomas. The vaccine is designed to stimulate an immune response against tumor cells expressing these antigens by presenting the selected HLA-A2-restricted epitopes to cytotoxic T lymphocytes. It is typically administered with immunological adjuvants such as GM-CSF and PF3512676 in Montanide ISA oil to enhance immunogenicity. Developed primarily for the treatment of melanoma, this approach aims to induce antigen-specific T cell responses targeting malignant melanocytes[2][3][4][5].

Other names

multi-antigen melanoma peptide vaccineMART-1/gp100/tyrosinase peptides-loaded vaccine